In fact, administration of NG-monomethyl-L-arginine (L-NMMA), a non-selective inhibitor of NOS (e.g., enzymes that produce NO) induced a decrease of glucose uptake in healthy and participants with type 2 diabetes (Bradley et al., 1999; Kingwell et al., 2002). The gene discussed is NOS2; the disease is type 2 diabetes mellitus.